|
1
|
A prospective natural-history study of coronary atherosclerosis.
|
N Engl J Med
|
2011
|
10.66
|
|
2
|
A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation.
|
J Am Coll Cardiol
|
2004
|
5.67
|
|
3
|
Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
|
N Engl J Med
|
2002
|
4.25
|
|
4
|
Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization And Urgent Intervention Triage Strategy (ACUITY) substudy.
|
Circulation
|
2010
|
3.95
|
|
5
|
Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.
|
N Engl J Med
|
2010
|
3.27
|
|
6
|
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.
|
Lancet
|
2009
|
2.82
|
|
7
|
Comparison of clinical interpretation with visual assessment and quantitative coronary angiography in patients undergoing percutaneous coronary intervention in contemporary practice: the Assessing Angiography (A2) project.
|
Circulation
|
2013
|
2.81
|
|
8
|
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
|
Lancet
|
2007
|
2.67
|
|
9
|
A risk score to predict bleeding in patients with acute coronary syndromes.
|
J Am Coll Cardiol
|
2010
|
2.62
|
|
10
|
Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial.
|
JAMA
|
2005
|
2.61
|
|
11
|
Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial.
|
JAMA
|
2008
|
2.59
|
|
12
|
Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials.
|
J Am Coll Cardiol
|
2008
|
2.54
|
|
13
|
Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial.
|
J Am Coll Cardiol
|
2011
|
2.49
|
|
14
|
Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial.
|
Circulation
|
2009
|
2.47
|
|
15
|
Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables.
|
Am J Cardiol
|
2005
|
2.42
|
|
16
|
Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies.
|
Circulation
|
2009
|
2.40
|
|
17
|
The impact of the coronary collateral circulation on mortality: a meta-analysis.
|
Eur Heart J
|
2011
|
2.33
|
|
18
|
A volumetric intravascular ultrasound comparison of early drug-eluting stent thrombosis versus restenosis.
|
JACC Cardiovasc Interv
|
2009
|
2.30
|
|
19
|
Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer.
|
Circulation
|
2004
|
2.29
|
|
20
|
Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial.
|
Circulation
|
2012
|
2.26
|
|
21
|
A blood-based gene expression test for obstructive coronary artery disease tested in symptomatic nondiabetic patients referred for myocardial perfusion imaging the COMPASS study.
|
Circ Cardiovasc Genet
|
2013
|
2.18
|
|
22
|
Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction.
|
Circulation
|
2011
|
2.18
|
|
23
|
Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial.
|
J Am Coll Cardiol
|
2003
|
2.18
|
|
24
|
Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
|
J Am Coll Cardiol
|
2010
|
2.15
|
|
25
|
Serial angiographic follow-up of sirolimus-eluting stents for unprotected left main coronary artery revascularization.
|
J Am Coll Cardiol
|
2006
|
2.12
|
|
26
|
The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.
|
J Invasive Cardiol
|
2010
|
2.10
|
|
27
|
Drug-eluting balloon angioplasty for in-stent restenosis: a systematic review and meta-analysis of randomised controlled trials.
|
Heart
|
2013
|
2.09
|
|
28
|
Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction.
|
J Am Coll Cardiol
|
2002
|
1.95
|
|
29
|
Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction.
|
Eur Heart J
|
2007
|
1.92
|
|
30
|
Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial.
|
Circulation
|
2009
|
1.88
|
|
31
|
Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
|
J Am Coll Cardiol
|
2009
|
1.86
|
|
32
|
Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction.
|
J Am Coll Cardiol
|
2004
|
1.84
|
|
33
|
Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention.
|
J Invasive Cardiol
|
2003
|
1.77
|
|
34
|
Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study.
|
J Am Coll Cardiol
|
2005
|
1.73
|
|
35
|
Bifurcation coronary lesions treated with the "crush" technique: an intravascular ultrasound analysis.
|
J Am Coll Cardiol
|
2005
|
1.72
|
|
36
|
Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis.
|
Circulation
|
2004
|
1.72
|
|
37
|
Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction.
|
N Engl J Med
|
2009
|
1.72
|
|
38
|
Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
|
J Am Coll Cardiol
|
2011
|
1.72
|
|
39
|
Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial.
|
Lancet
|
2002
|
1.72
|
|
40
|
Outcomes of patients with coronary artery perforation complicating percutaneous coronary intervention and correlations with the type of adjunctive antithrombotic therapy: pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials.
|
J Interv Cardiol
|
2009
|
1.64
|
|
41
|
Increased CK-MB release is a "trade-off" for optimal stent implantation: an intravascular ultrasound study.
|
J Am Coll Cardiol
|
2003
|
1.62
|
|
42
|
Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial).
|
Am J Cardiol
|
2006
|
1.62
|
|
43
|
Short- and long-term results after multivessel stenting in diabetic patients.
|
J Am Coll Cardiol
|
2004
|
1.57
|
|
44
|
Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions.
|
Kidney Int
|
2005
|
1.57
|
|
45
|
Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial.
|
JACC Cardiovasc Interv
|
2009
|
1.54
|
|
46
|
A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
|
EuroIntervention
|
2013
|
1.53
|
|
47
|
Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
|
JACC Cardiovasc Interv
|
2011
|
1.53
|
|
48
|
Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score.
|
J Am Coll Cardiol
|
2005
|
1.52
|
|
49
|
Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction.
|
Circ Cardiovasc Interv
|
2009
|
1.51
|
|
50
|
Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial.
|
J Am Coll Cardiol
|
2012
|
1.51
|
|
51
|
Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials.
|
JACC Cardiovasc Interv
|
2011
|
1.50
|
|
52
|
Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial).
|
Am J Cardiol
|
2005
|
1.47
|
|
53
|
An evaluation of fluoroscopy time and correlation with outcomes after percutaneous coronary intervention.
|
J Invasive Cardiol
|
2007
|
1.46
|
|
54
|
Impact of bivalirudin therapy in high-risk patients with acute myocardial infarction: 1-year results from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial.
|
JACC Cardiovasc Interv
|
2010
|
1.46
|
|
55
|
Results of the Jostent coronary stent graft implantation in various clinical settings: procedural and follow-up results.
|
Catheter Cardiovasc Interv
|
2002
|
1.45
|
|
56
|
Randomized, double-blind, multicenter study of the polymer-based 17-beta estradiol-eluting stent for treatment of native coronary artery lesions: six-month results of the ETHOS I trial.
|
Catheter Cardiovasc Interv
|
2007
|
1.44
|
|
57
|
Radial versus femoral access for primary percutaneous coronary intervention: is there a preferred route to the heart?
|
Heart
|
2011
|
1.42
|
|
58
|
Plaque shift and distal embolism in patients with acute myocardial infarction: a volumetric intravascular ultrasound analysis from the HORIZONS-AMI trial.
|
Catheter Cardiovasc Interv
|
2013
|
1.41
|
|
59
|
The impact of the coronary collateral circulation on outcomes in patients with acute coronary syndromes: results from the ACUITY trial.
|
Heart
|
2013
|
1.41
|
|
60
|
Morphological changes and clinical impact of unstable plaques within untreated segments of acute myocardial infarction patients during a 3-year follow-up: an analysis from the HORIZONS-AMI trial.
|
Coron Artery Dis
|
2015
|
1.39
|
|
61
|
Balloon-based radiation therapy for treatment of in-stent restenosis in human coronary arteries: results from the BRITE I study.
|
Catheter Cardiovasc Interv
|
2002
|
1.38
|
|
62
|
Benefits of cutting balloon before stenting.
|
J Invasive Cardiol
|
2003
|
1.38
|
|
63
|
Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction.
|
Circulation
|
2003
|
1.38
|
|
64
|
Development of a blood-based gene expression algorithm for assessment of obstructive coronary artery disease in non-diabetic patients.
|
BMC Med Genomics
|
2011
|
1.37
|
|
65
|
Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial).
|
Am J Cardiol
|
2007
|
1.35
|
|
66
|
Use of a novel crossing and re-entry system in coronary chronic total occlusions that have failed standard crossing techniques: results of the FAST-CTOs (Facilitated Antegrade Steering Technique in Chronic Total Occlusions) trial.
|
JACC Cardiovasc Interv
|
2012
|
1.35
|
|
67
|
Strut coverage and late malapposition with paclitaxel-eluting stents compared with bare metal stents in acute myocardial infarction: optical coherence tomography substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial.
|
Circulation
|
2011
|
1.31
|
|
68
|
Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association.
|
Circulation
|
2005
|
1.30
|
|
69
|
Usefulness of a cobalt chromium coronary stent alloy.
|
Am J Cardiol
|
2003
|
1.29
|
|
70
|
When is door-to-balloon time critical? Analysis from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trials.
|
J Am Coll Cardiol
|
2010
|
1.28
|
|
71
|
Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction.
|
Eur Heart J
|
2005
|
1.24
|
|
72
|
Classification and potential mechanisms of intravascular ultrasound patterns of stent fracture.
|
Am J Cardiol
|
2009
|
1.23
|
|
73
|
Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial.
|
J Am Coll Cardiol
|
2004
|
1.21
|
|
74
|
Local versus general anesthesia for transcatheter aortic valve implantation (TAVR)--systematic review and meta-analysis.
|
BMC Med
|
2014
|
1.21
|
|
75
|
Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial.
|
Eur Heart J
|
2009
|
1.21
|
|
76
|
Intravascular ultrasound classification of plaque distribution in left main coronary artery bifurcations: where is the plaque really located?
|
Circ Cardiovasc Interv
|
2010
|
1.19
|
|
77
|
Stroke prevention by percutaneous closure of patent foramen ovale: a systematic review and meta-analysis.
|
Heart
|
2013
|
1.19
|
|
78
|
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
|
Am Heart J
|
2004
|
1.19
|
|
79
|
Assessing intermediate left main coronary lesions using intravascular ultrasound.
|
Am Heart J
|
2007
|
1.18
|
|
80
|
Drug-eluting stents in the treatment of intermediate lesions: pooled analysis from four randomized trials.
|
J Am Coll Cardiol
|
2006
|
1.17
|
|
81
|
Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
|
J Am Coll Cardiol
|
2010
|
1.16
|
|
82
|
Intravascular ultrasound assessment of ulcerated ruptured plaques: a comparison of culprit and nonculprit lesions of patients with acute coronary syndromes and lesions in patients without acute coronary syndromes.
|
Circulation
|
2003
|
1.16
|
|
83
|
Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
|
J Am Coll Cardiol
|
2009
|
1.16
|
|
84
|
Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes.
|
JACC Cardiovasc Imaging
|
2012
|
1.14
|
|
85
|
Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
|
JACC Cardiovasc Interv
|
2013
|
1.14
|
|
86
|
Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure.
|
Catheter Cardiovasc Interv
|
2002
|
1.12
|
|
87
|
Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
|
Circulation
|
2004
|
1.12
|
|
88
|
Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: analysis from the CADILLAC trial.
|
Am Heart J
|
2006
|
1.12
|
|
89
|
Randomized trial of 90Sr/90Y beta-radiation versus placebo control for treatment of in-stent restenosis.
|
Circulation
|
2002
|
1.11
|
|
90
|
Paclitaxel-eluting stents compared with bare metal stents in diabetic patients with acute myocardial infarction: the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial.
|
Circ Cardiovasc Interv
|
2011
|
1.11
|
|
91
|
Definitions and methodology for the grayscale and radiofrequency intravascular ultrasound and coronary angiographic analyses.
|
JACC Cardiovasc Imaging
|
2012
|
1.10
|
|
92
|
Magnitude and impact of treatment delays on weeknights and weekends in patients undergoing primary angioplasty for acute myocardial infarction (the cadillac trial).
|
Am J Cardiol
|
2004
|
1.09
|
|
93
|
Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial).
|
Am J Cardiol
|
2007
|
1.09
|
|
94
|
Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction.
|
J Am Coll Cardiol
|
2004
|
1.09
|
|
95
|
Intravascular ultrasound study of patterns of calcium in ruptured coronary plaques.
|
Am J Cardiol
|
2005
|
1.09
|
|
96
|
Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
|
JACC Cardiovasc Interv
|
2011
|
1.08
|
|
97
|
Long-term outcome of patients treated with repeat percutaneous coronary intervention after failure of gamma-brachytherapy for the treatment of in-stent restenosis.
|
Circulation
|
2002
|
1.08
|
|
98
|
5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
|
J Am Coll Cardiol
|
2009
|
1.07
|
|
99
|
Comparison of angiographic and intravascular ultrasonic detection of myocardial bridging of the left anterior descending coronary artery.
|
Am J Cardiol
|
2008
|
1.07
|
|
100
|
Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention.
|
Am J Cardiol
|
2004
|
1.05
|
|
101
|
Impact of anemia on clinical outcomes of patients with ST-segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI trial).
|
Am J Cardiol
|
2010
|
1.04
|
|
102
|
Intravascular ultrasound findings of early stent thrombosis after primary percutaneous intervention in acute myocardial infarction: a Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) substudy.
|
Circ Cardiovasc Interv
|
2011
|
1.04
|
|
103
|
SYNTAX score reproducibility and variability between interventional cardiologists, core laboratory technicians, and quantitative coronary measurements.
|
Circ Cardiovasc Interv
|
2011
|
1.04
|
|
104
|
Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
|
J Am Coll Cardiol
|
2004
|
1.04
|
|
105
|
Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction.
|
Am Heart J
|
2006
|
1.04
|
|
106
|
Adverse cardiovascular events arising from atherosclerotic lesions with and without angiographic disease progression.
|
JACC Cardiovasc Imaging
|
2012
|
1.02
|
|
107
|
Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS-SWITCH analysis.
|
J Am Coll Cardiol
|
2011
|
1.01
|
|
108
|
Residual plaque burden in patients with acute coronary syndromes after successful percutaneous coronary intervention.
|
JACC Cardiovasc Imaging
|
2012
|
1.01
|
|
109
|
Nonuniform strut distribution correlates with more neointimal hyperplasia after sirolimus-eluting stent implantation.
|
Circulation
|
2004
|
1.01
|
|
110
|
Characteristics and clinical significance of angiographically mild lesions in acute coronary syndromes.
|
JACC Cardiovasc Imaging
|
2012
|
0.99
|
|
111
|
Sex-based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: three year results from the HORIZONS-AMI trial.
|
Catheter Cardiovasc Interv
|
2014
|
0.98
|
|
112
|
Whole blood gene expression testing for coronary artery disease in nondiabetic patients: major adverse cardiovascular events and interventions in the PREDICT trial.
|
J Cardiovasc Transl Res
|
2012
|
0.97
|
|
113
|
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
|
JACC Cardiovasc Interv
|
2010
|
0.97
|
|
114
|
Incidence, mechanisms, predictors, and clinical impact of acute and late stent malapposition after primary intervention in patients with acute myocardial infarction: an intravascular ultrasound substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial.
|
Circulation
|
2010
|
0.96
|
|
115
|
Angiographic patterns of drug-eluting stent restenosis and one-year outcomes after treatment with repeated percutaneous coronary intervention.
|
Am J Cardiol
|
2008
|
0.96
|
|
116
|
Predictors of reperfusion delay in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention from the HORIZONS-AMI trial.
|
Am J Cardiol
|
2010
|
0.96
|
|
117
|
Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions.
|
Am J Cardiol
|
2004
|
0.95
|
|
118
|
SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease.
|
Am Heart J
|
2009
|
0.95
|
|
119
|
Impact and determinants of left ventricular function in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction.
|
Am J Cardiol
|
2005
|
0.95
|
|
120
|
5-year follow-up of polytetrafluoroethylene-covered stents compared with bare-metal stents in aortocoronary saphenous vein grafts the randomized BARRICADE (barrier approach to restenosis: restrict intima to curtail adverse events) trial.
|
JACC Cardiovasc Interv
|
2011
|
0.94
|
|
121
|
New approaches for the assessment of vessel sizes in quantitative (cardio-)vascular X-ray analysis.
|
Int J Cardiovasc Imaging
|
2009
|
0.93
|
|
122
|
Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial).
|
Am J Cardiol
|
2011
|
0.93
|
|
123
|
Clinical validation of the new T- and Y-shape models for the quantitative analysis of coronary bifurcations: an interobserver variability study.
|
Catheter Cardiovasc Interv
|
2012
|
0.92
|
|
124
|
Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
|
Circulation
|
2003
|
0.92
|
|
125
|
Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
|
J Am Coll Cardiol
|
2008
|
0.92
|
|
126
|
Almanac 2013: acute coronary syndromes.
|
Heart
|
2013
|
0.91
|
|
127
|
Importance of mitral regurgitation inpatients undergoing percutaneous coronary intervention for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
|
J Am Coll Cardiol
|
2004
|
0.91
|
|
128
|
A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
|
J Am Coll Cardiol
|
2008
|
0.91
|
|
129
|
Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction.
|
J Am Coll Cardiol
|
2005
|
0.91
|
|
130
|
Angiographic results of the first human experience with the Biolimus A9 drug-eluting stent for de novo coronary lesions.
|
Am J Cardiol
|
2006
|
0.90
|
|
131
|
Impact of collateral flow on myocardial reperfusion and infarct size in patients undergoing primary angioplasty for acute myocardial infarction.
|
Am Heart J
|
2007
|
0.90
|
|
132
|
Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial.
|
Am Heart J
|
2011
|
0.90
|
|
133
|
Impact of myocardial bridge on clinical outcome after coronary stent placement.
|
Am J Cardiol
|
2009
|
0.89
|
|
134
|
Intravascular ultrasonic assessment of stent diameters derived from manufacturer's compliance charts.
|
Am J Cardiol
|
2005
|
0.89
|
|
135
|
Effectiveness of drug-eluting stent implantation for patients with unprotected left main coronary artery stenosis.
|
Am J Cardiol
|
2008
|
0.89
|
|
136
|
The relationship between attenuated plaque identified by intravascular ultrasound and no-reflow after stenting in acute myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
|
JACC Cardiovasc Interv
|
2011
|
0.89
|
|
137
|
Relation between leucocyte count, myonecrosis, myocardial perfusion, and outcomes following primary angioplasty.
|
Am J Cardiol
|
2007
|
0.89
|
|
138
|
Contemporary outcomes of rescue percutaneous coronary intervention for acute myocardial infarction: comparison with primary angioplasty and the role of distal protection devices (EMERALD trial).
|
Am Heart J
|
2008
|
0.89
|
|
139
|
Dedicated bifurcation analysis: basic principles.
|
Int J Cardiovasc Imaging
|
2011
|
0.88
|
|
140
|
The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial.
|
Eur Heart J Acute Cardiovasc Care
|
2013
|
0.88
|
|
141
|
Novel QCA methodologies and angiographic scores.
|
Int J Cardiovasc Imaging
|
2011
|
0.88
|
|
142
|
Nonrandomized comparison of coronary stenting under intravascular ultrasound guidance of direct stenting without predilation versus conventional predilation with a semi-compliant balloon versus predilation with a new scoring balloon.
|
Am J Cardiol
|
2007
|
0.87
|
|
143
|
Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction.
|
Am Heart J
|
2006
|
0.87
|
|
144
|
The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale.
|
Am Heart J
|
2008
|
0.87
|
|
145
|
Intravascular ultrasound comparison of the retrograde versus antegrade approach to percutaneous intervention for chronic total coronary occlusions.
|
JACC Cardiovasc Interv
|
2009
|
0.87
|
|
146
|
Predictors and implications of stent thrombosis in non-ST-segment elevation acute coronary syndromes: the ACUITY Trial.
|
Circ Cardiovasc Interv
|
2011
|
0.86
|
|
147
|
Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials).
|
Am J Cardiol
|
2006
|
0.86
|
|
148
|
Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
|
JACC Cardiovasc Interv
|
2010
|
0.86
|
|
149
|
Surgical versus percutaneous revascularization for multivessel disease in patients with acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
|
JACC Cardiovasc Interv
|
2010
|
0.86
|
|
150
|
A prospective registry to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions using the "crush technique".
|
Am J Cardiol
|
2006
|
0.86
|
|
151
|
9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study.
|
J Am Coll Cardiol
|
2009
|
0.86
|
|
152
|
Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial.
|
EuroIntervention
|
2011
|
0.86
|
|
153
|
Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction.
|
J Am Coll Cardiol
|
2006
|
0.86
|
|
154
|
Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy.
|
JACC Cardiovasc Interv
|
2009
|
0.86
|
|
155
|
Gender-specific outcomes after sirolimus-eluting stent implantation.
|
J Am Coll Cardiol
|
2007
|
0.86
|
|
156
|
Intravascular ultrasound assessment of the incidence and predictors of edge dissections after drug-eluting stent implantation.
|
JACC Cardiovasc Interv
|
2009
|
0.85
|
|
157
|
Short- and long-term outcomes after stent-assisted percutaneous treatment of saphenous vein grafts in the drug-eluting stent era.
|
Am J Cardiol
|
2007
|
0.85
|
|
158
|
Coronary collaterals and risk for restenosis after percutaneous coronary interventions: a meta-analysis.
|
BMC Med
|
2012
|
0.85
|
|
159
|
Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial.
|
J Thromb Thrombolysis
|
2011
|
0.85
|
|
160
|
Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction.
|
Am J Cardiol
|
2005
|
0.85
|
|
161
|
Efficacy and safety of FIREHAWK® abluminal groove filled biodegradable polymer sirolimus-eluting stents for the treatment of long coronary lesions: nine-month angiographic and one-year clinical results from TARGET I trial long cohort.
|
Chin Med J (Engl)
|
2013
|
0.84
|
|
162
|
Non-fibroatheroma lesion phenotype and long-term clinical outcomes: a substudy analysis from the PROSPECT study.
|
JACC Cardiovasc Imaging
|
2013
|
0.84
|
|
163
|
Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial).
|
Am J Cardiol
|
2005
|
0.84
|
|
164
|
First report of a novel abluminal groove filled biodegradable polymer rapamycin-eluting stent in de novo coronary artery disease: results of the first in man FIREHAWK trial.
|
Chin Med J (Engl)
|
2012
|
0.83
|
|
165
|
Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial.
|
EuroIntervention
|
2011
|
0.83
|
|
166
|
Prognostic significance of cerebrovascular and peripheral arterial disease in patients having percutaneous coronary interventions.
|
Am J Cardiol
|
2004
|
0.83
|
|
167
|
The collateral circulation of the heart.
|
BMC Med
|
2013
|
0.83
|
|
168
|
Predictors and implications of coronary infarct artery patency at initial angiography in patients with acute myocardial infarction (from the CADILLAC and HORIZONS-AMI Trials).
|
Am J Cardiol
|
2011
|
0.82
|
|
169
|
Predictors of suboptimal TIMI flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS-AMI trial.
|
EuroIntervention
|
2013
|
0.82
|
|
170
|
Prospective, multicenter study of thrombectomy in patients with acute myocardial infarction: the X-Tract AMI registry.
|
J Interv Cardiol
|
2007
|
0.82
|
|
171
|
Rationale and design of the INFUSE-AMI study: A 2 × 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction.
|
Am Heart J
|
2011
|
0.82
|
|
172
|
Outcome after acute incomplete sirolimus-eluting stent apposition as assessed by serial intravascular ultrasound.
|
Am J Cardiol
|
2006
|
0.82
|
|
173
|
Usefulness of minimum stent cross sectional area as a predictor of angiographic restenosis after primary percutaneous coronary intervention in acute myocardial infarction (from the HORIZONS-AMI Trial IVUS substudy).
|
Am J Cardiol
|
2011
|
0.82
|
|
174
|
Comparison of in-hospital and one-year outcomes after multiple coronary arterial stenting in patients > or =80 years old versus those <80 years old.
|
Am J Cardiol
|
2003
|
0.82
|
|
175
|
Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial).
|
Am J Cardiol
|
2004
|
0.81
|
|
176
|
A trial comparing rheolytic thrombectomy with intracoronary urokinase for coronary and vein graft thrombus (the Vein Graft AngioJet Study [VeGAS 2]).
|
Am J Cardiol
|
2002
|
0.81
|
|
177
|
Volumetric intravascular ultrasound analysis of Paclitaxel-eluting and bare metal stents in acute myocardial infarction: the harmonizing outcomes with revascularization and stents in acute myocardial infarction intravascular ultrasound substudy.
|
Circulation
|
2009
|
0.81
|
|
178
|
Long-term follow-up of patients after gamma intracoronary brachytherapy failure (from GAMMA-I, GAMMA-II, and SCRIPPS-III).
|
Am J Cardiol
|
2003
|
0.81
|
|
179
|
Impact of symptomatic peripheral arterial disease on 1-year mortality in patients undergoing percutaneous coronary interventions.
|
J Endovasc Ther
|
2004
|
0.81
|
|
180
|
Intravascular ultrasound assessment of lesions with target vessel failure after sirolimus-eluting stent implantation.
|
Am J Cardiol
|
2005
|
0.81
|
|
181
|
Postprocedure creatine kinase-MB elevation and baseline left ventricular dysfunction predict one-year mortality after percutaneous coronary intervention.
|
Am J Cardiol
|
2002
|
0.81
|
|
182
|
Comparison of outcomes in men versus women having percutaneous coronary interventions in small coronary arteries.
|
Am J Cardiol
|
2003
|
0.81
|
|
183
|
Safety and efficacy of high- versus low-dose aspirin after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
|
JACC Cardiovasc Interv
|
2012
|
0.81
|
|
184
|
Impact of infarct-related artery patency before primary PCI on outcome in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial.
|
EuroIntervention
|
2013
|
0.81
|
|
185
|
Prognostic impact of multivessel versus culprit vessel only percutaneous intervention for patients with multivessel coronary artery disease presenting with acute coronary syndrome.
|
EuroIntervention
|
2015
|
0.80
|
|
186
|
Correlation of coronary arterial remodeling determined by intravascular ultrasound with angiographic diameter reduction of 20% to 60%.
|
Am J Cardiol
|
2003
|
0.80
|
|
187
|
Impact of smoking on outcomes of patients with ST-segment elevation myocardial infarction (from the HORIZONS-AMI Trial).
|
Am J Cardiol
|
2011
|
0.80
|
|
188
|
Optimal final lumen area and predictors of target lesion revascularization after stent implantation in small coronary arteries.
|
Am J Cardiol
|
2003
|
0.80
|
|
189
|
Comparison of one-year outcomes after percutaneous coronary intervention among current smokers, ex-smokers, and nonsmokers.
|
Am J Cardiol
|
2002
|
0.80
|
|
190
|
Clinical implications for diffusion-weighted MRI brain lesions associated with transcatheter aortic valve replacement.
|
Catheter Cardiovasc Interv
|
2013
|
0.80
|
|
191
|
Advances in the hospital management of patients following an out of hospital cardiac arrest.
|
Heart
|
2012
|
0.80
|
|
192
|
Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors.
|
Am J Cardiol
|
2002
|
0.80
|
|
193
|
Long-term prognosis of patients presenting with ST-segment elevation myocardial infarction with no significant coronary artery disease (from the HORIZONS-AMI trial).
|
Am J Cardiol
|
2012
|
0.80
|
|
194
|
Relation between late patency of the infarct-related artery, left ventricular function, and clinical outcomes after primary percutaneous intervention for acute myocardial infarction (CADILLAC trial).
|
Am J Cardiol
|
2004
|
0.80
|
|
195
|
Complementary prognostic utility of myocardial blush grade and ST-segment resolution after primary percutaneous coronary intervention: analysis from the HORIZONS-AMI trial.
|
Am Heart J
|
2013
|
0.80
|
|
196
|
Comparison of clinical outcomes using stents versus no stents after percutaneous coronary intervention for proximal left anterior descending versus proximal right and left circumflex coronary arteries.
|
Am J Cardiol
|
2002
|
0.80
|
|
197
|
Safety of an aspirin-alone regimen after intracoronary stenting with a heparin-coated stent: final results of the HOPE (HEPACOAT and an Antithrombotic Regimen of Aspirin Alone) study.
|
Circulation
|
2003
|
0.80
|
|
198
|
The Future REvascularization Evaluation in patients with Diabetes mellitus: optimal management of Multivessel disease (FREEDOM) trial: clinical and angiographic profile at study entry.
|
Am Heart J
|
2012
|
0.80
|
|
199
|
Age- and gender-related changes in plaque composition in patients with acute coronary syndrome: the PROSPECT study.
|
EuroIntervention
|
2012
|
0.80
|
|
200
|
Minimally invasive direct coronary artery bypass (MIDCAB) versus coronary artery stenting for elective revascularization of the left anterior descending artery.
|
Am J Cardiol
|
2002
|
0.79
|
|
201
|
Drug eluting balloons for de novo coronary lesions - a systematic review and meta-analysis.
|
BMC Med
|
2013
|
0.79
|
|
202
|
Usefulness of routine unfractionated heparin infusion following primary percutaneous coronary intervention for acute myocardial infarction in patients not receiving glycoprotein IIb/IIIa inhibitors.
|
Am J Cardiol
|
2006
|
0.79
|
|
203
|
7-hexanoyltaxol-eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE).
|
Circulation
|
2002
|
0.79
|
|
204
|
Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial).
|
Am J Cardiol
|
2003
|
0.79
|
|
205
|
Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus-containing coronary arteries.
|
J Am Coll Cardiol
|
2003
|
0.79
|
|
206
|
Five-year clinical and angiographic follow-up after intracoronary iridium-192 radiation therapy.
|
Cardiovasc Radiat Med
|
2003
|
0.79
|
|
207
|
Prognostic significance of elevated baseline troponin in patients with acute coronary syndromes and chronic kidney disease treated with different antithrombotic regimens: a substudy from the ACUITY trial.
|
Circ Cardiovasc Interv
|
2012
|
0.79
|
|
208
|
Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
|
Am Heart J
|
2006
|
0.79
|
|
209
|
Clinical outcomes after heterogeneous overlap stenting with drug-eluting stents and bare-metal stents for de novo coronary artery narrowings.
|
Am J Cardiol
|
2007
|
0.78
|
|
210
|
Comparison of the angiographic outcomes after beta versus gamma vascular brachytherapy for treatment of in-stent restenosis.
|
Am J Cardiol
|
2003
|
0.78
|
|
211
|
Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial).
|
Am J Cardiol
|
2011
|
0.78
|
|
212
|
Minimally invasive coronary artery bypass grafting versus stenting for patients with proximal left anterior descending coronary artery disease.
|
Am J Cardiol
|
2004
|
0.78
|
|
213
|
The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) trial.
|
JACC Cardiovasc Interv
|
2009
|
0.78
|
|
214
|
Almanac 2013: Acute coronary syndromes.
|
Acta Cardiol
|
2014
|
0.78
|
|
215
|
Impact of bifurcation target lesion on angiographic, electrocardiographic, and clinical outcomes of patients undergoing primary percutaneous coronary intervention (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial).
|
EuroIntervention
|
2013
|
0.78
|
|
216
|
Delivered dose and vascular response after beta-radiation for in-stent restenosis: retrospective dosimetry and volumetric intravascular ultrasound analysis.
|
Circulation
|
2002
|
0.78
|
|
217
|
Comparison of direct stenting with conventional stent implantation in acute myocardial infarction.
|
Am J Cardiol
|
2011
|
0.78
|
|
218
|
Vascular remodeling and plaque composition between focal and diffuse coronary lesions assessed by intravascular ultrasound.
|
Am J Cardiol
|
2004
|
0.78
|
|
219
|
Volumetric intravascular ultrasound assessment of neointimal hyperplasia and nonuniform stent strut distribution in sirolimus-eluting stent restenosis.
|
Am J Cardiol
|
2006
|
0.78
|
|
220
|
Pre-hypertension: another 'pseudodisease'?
|
BMC Med
|
2013
|
0.77
|
|
221
|
Targeted anti-inflammatory systemic therapy for restenosis: the Biorest Liposomal Alendronate with Stenting sTudy (BLAST)-a double blind, randomized clinical trial.
|
Am Heart J
|
2012
|
0.77
|
|
222
|
Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial.
|
Am Heart J
|
2011
|
0.77
|
|
223
|
Relation between the degree of procedural anticoagulation and complications after coronary stent implantation.
|
Am J Cardiol
|
2003
|
0.77
|
|
224
|
Intravascular brachytherapy for native coronary ostial in-stent restenotic lesions.
|
J Am Coll Cardiol
|
2003
|
0.77
|
|
225
|
An intravascular ultrasound appraisal of atherosclerotic plaque distribution in diseased coronary arteries.
|
Am Heart J
|
2012
|
0.77
|
|
226
|
Usefulness of beta radiation for de novo and in-stent restenotic lesions in saphenous vein grafts.
|
Am J Cardiol
|
2003
|
0.77
|
|
227
|
Creatine kinase-MB enzyme elevation and long-term clinical events after successful coronary stenting in lesions with ruptured plaque.
|
Am J Cardiol
|
2005
|
0.77
|
|
228
|
Clinical and angiographic outcomes with an everolimus-eluting stent in large coronary arteries: the SPIRIT III 4.0 mm registry.
|
Catheter Cardiovasc Interv
|
2010
|
0.77
|
|
229
|
Operator versus core laboratory assessment of angiographic reperfusion markers in patients undergoing primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction.
|
Circ Cardiovasc Interv
|
2012
|
0.77
|
|
230
|
Usefulness of atrial fibrillation as a marker of outcome after percutaneous coronary intervention.
|
Am J Cardiol
|
2003
|
0.77
|
|
231
|
Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial.
|
EuroIntervention
|
2010
|
0.77
|
|
232
|
Two-year clinical follow-up of 90Sr/90 Y beta-radiation versus placebo control for the treatment of in-stent restenosis.
|
Am Heart J
|
2005
|
0.77
|
|
233
|
Intravascular ultrasonic differences between aorto-ostial and shaft narrowing in saphenous veins used as aortocoronary bypass grafts.
|
Am J Cardiol
|
2006
|
0.77
|
|
234
|
Treatment of diffuse in-stent restenosis with drug-eluting stents vs. intracoronary beta-radiation therapy: INDEED Study.
|
Int J Cardiol
|
2008
|
0.76
|
|
235
|
Percutaneous coronary revascularization using a trilayer metal phosphorylcholine-coated zotarolimus-eluting stent.
|
Am J Cardiol
|
2007
|
0.76
|
|
236
|
Dominant contribution of negative remodeling to development of significant coronary bifurcation narrowing.
|
Am J Cardiol
|
2003
|
0.76
|
|
237
|
Almanac 2013: novel non-coronary cardiac interventions.
|
Heart
|
2013
|
0.76
|
|
238
|
Randomized comparison of carbon ion-implanted stent versus bare metal stent in coronary artery disease: the Asian Pacific Multicenter Arthos Stent Study (PASS) trial.
|
Am Heart J
|
2005
|
0.76
|
|
239
|
Local delivery of paclitaxel in the treatment of peripheral arterial disease.
|
Eur J Clin Invest
|
2015
|
0.76
|
|
240
|
Randomised study of a bioabsorbable polymer-coated sirolimus-eluting stent: results of the DESSOLVE II trial.
|
EuroIntervention
|
2015
|
0.76
|
|
241
|
Optimal duration of clopidogrel therapy: the shorter the longer?
|
Eur Heart J
|
2012
|
0.76
|
|
242
|
Significance of prior percutaneous revascularisation in patients with acute coronary syndromes: insights from the prospective PROSPECT registry.
|
EuroIntervention
|
2016
|
0.76
|
|
243
|
Relationship between ST-segment recovery and clinical outcomes after primary percutaneous coronary intervention: the HORIZONS-AMI ECG substudy report.
|
Circ Cardiovasc Interv
|
2013
|
0.75
|
|
244
|
Response to letters regarding article, "comparison of clinical interpretation with visual assessment and quantitative coronary angiography in patients undergoing percutaneous coronary intervention in contemporary practice: the assessing angiography (A2) project".
|
Circulation
|
2013
|
0.75
|
|
245
|
Relation of final lumen dimensions in saphenous vein grafts after stent implantation to outcome.
|
Am J Cardiol
|
2004
|
0.75
|
|
246
|
Drug-eluting balloon for instent restenosis--the author's reply.
|
Heart
|
2013
|
0.75
|
|
247
|
Bleeding complications in percutaneous coronary interventions.
|
Cardiology
|
2013
|
0.75
|
|
248
|
Who should treat coronary left main disease--a battle of the titans?
|
Cardiology
|
2011
|
0.75
|
|
249
|
[Sirolimus-eluting stents for the treatment of stenoses in small coronary arteries: what have we learned?].
|
Arq Bras Cardiol
|
2006
|
0.75
|
|
250
|
[Not Available].
|
Heart
|
2013
|
0.75
|
|
251
|
Safety and efficacy of a novel device for treatment of thrombotic and atherosclerotic lesions in native coronary arteries and saphenous vein grafts: results from the multicenter X-Sizer for treatment of thrombus and atherosclerosis in coronary applications trial (X-TRACT) study.
|
Catheter Cardiovasc Interv
|
2003
|
0.75
|
|
252
|
Lumen Measurements From Quantitative Coronary Angiography and IVUS: A PROSPECT Substudy.
|
JACC Cardiovasc Imaging
|
2015
|
0.75
|
|
253
|
Angiographic and clinical outcomes at 8 months of cutting balloon angioplasty and beta-brachytherapy for native vessel in-stent restenosis (BETACUT): results from a stopped randomized controlled trial.
|
Catheter Cardiovasc Interv
|
2005
|
0.75
|
|
254
|
Is accurate intravascular ultrasound evaluation of the left circumflex ostium from a left anterior descending to left main pullback possible?
|
Am J Cardiol
|
2010
|
0.75
|
|
255
|
Selection and timing for invasive therapy in non-ST-segment-elevation acute coronary syndrome.
|
Expert Rev Cardiovasc Ther
|
2013
|
0.75
|
|
256
|
Prognostic significance of coronary thrombus in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a subanalysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
|
JACC Cardiovasc Interv
|
2011
|
0.75
|
|
257
|
Comparison of frequency of hemorrhagic stroke in patients <75 years versus > or =75 years of age among patients receiving glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions.
|
Am J Cardiol
|
2004
|
0.75
|
|
258
|
The randomised study of the double dose versus single dose sirolimus-eluting stent for the treatment of diabetic patients with de novo coronary lesions.
|
EuroIntervention
|
2006
|
0.75
|
|
259
|
Acute and long-term outcomes of cutting balloon angioplasty followed by gamma brachytherapy for in-stent restenosis.
|
Am J Cardiol
|
2003
|
0.75
|
|
260
|
Almanac 2013: novel non-coronary cardiac interventions.
|
Anadolu Kardiyol Derg
|
2013
|
0.75
|
|
261
|
Feasibility and efficacy of tandem positioning on angiographic and clinical outcomes in the Intimal Hyperplasia Inhibition with Beta In-Stent Trial.
|
Am J Cardiol
|
2003
|
0.75
|
|
262
|
Outcomes of bail-out stenting for suboptimal balloon angioplasty during primary intervention in acute myocardial infarction (The CADILLAC trial).
|
Am J Cardiol
|
2003
|
0.75
|
|
263
|
Comparison of effect of glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions on risk of hemorrhagic stroke in patients >or=75 years of age versus those <75 years of age.
|
Am J Cardiol
|
2003
|
0.75
|
|
264
|
Late vascular response to repeat stenting for in-stent restenosis with and without radiation: an intravascular ultrasound volumetric analysis.
|
Circulation
|
2002
|
0.75
|
|
265
|
Will this trial change my practice? TASTE - a randomised registry on thrombus aspiration in primary PCI with a 30-day endpoint.
|
EuroIntervention
|
2014
|
0.75
|
|
266
|
Safety of beta radiation exposure to the non-target segment: an intravascular ultrasound dosimetric analysis.
|
J Invasive Cardiol
|
2006
|
0.75
|
|
267
|
Intravascular ultrasound findings of stent fractures in patients with Sirolimus- and Paclitaxel-eluting stents.
|
Am J Cardiol
|
2010
|
0.75
|
|
268
|
Tools and Techniques - Clinical: Embolic protection devices in transcatheter aortic valve implantation.
|
EuroIntervention
|
2015
|
0.75
|
|
269
|
Mid-term results of everolimus-eluting stent in a Japanese population compared with a US randomized cohort: SPIRIT III Japan Registry with harmonization by doing.
|
J Invasive Cardiol
|
2012
|
0.75
|
|
270
|
Diagnosing and characterizing coronary artery disease in women: developments in noninvasive and invasive imaging techniques.
|
J Cardiovasc Transl Res
|
2013
|
0.75
|
|
271
|
Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study.
|
EuroIntervention
|
2013
|
0.75
|
|
272
|
Almanac 2013: acute coronary syndromes.
|
Anadolu Kardiyol Derg
|
2013
|
0.75
|
|
273
|
Implications of the presence and length of "geographic miss" on restenosis and the edge phenomenon in the INHIBIT trial.
|
Am J Cardiol
|
2003
|
0.75
|
|
274
|
Predictors of recurrent in-stent restenosis after beta-radiation: An analysis from the START 40/20 trial.
|
J Interv Cardiol
|
2006
|
0.75
|
|
275
|
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.
|
Am Heart J
|
2004
|
0.75
|
|
276
|
Almanac 2013: novel non-coronary cardiac interventions.
|
Wien Klin Wochenschr
|
2013
|
0.75
|
|
277
|
Clinical and angiographic outcomes after use of 90Strontium/90Yttrium beta radiation for the treatment of in-stent restenosis: results from the Stents and Radiation Therapy 40 (START 40) registry.
|
Int J Radiat Oncol Biol Phys
|
2002
|
0.75
|
|
278
|
Almanac 2013: acute coronary syndromes.
|
Wien Klin Wochenschr
|
2014
|
0.75
|
|
279
|
Implications of pre-procedural TIMI flow in patients with non ST-segment elevation acute coronary syndromes undergoing percutaneous coronary revascularization: insights from the ACUITY trial.
|
Int J Cardiol
|
2012
|
0.75
|
|
280
|
Implications of myocardial reperfusion on survival in women versus men with acute myocardial infarction undergoing primary coronary intervention.
|
Am J Cardiol
|
2013
|
0.75
|
|
281
|
Treatment of left main and multivessel disease in the drug-eluting stent era.
|
Rev Cardiovasc Med
|
2009
|
0.75
|
|
282
|
Treatment of restenotic drug-eluting stents: an intravascular ultrasound analysis.
|
J Invasive Cardiol
|
2007
|
0.75
|
|
283
|
Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials.
|
Eur Heart J
|
2017
|
0.75
|
|
284
|
Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction.
|
J Interv Cardiol
|
2009
|
0.75
|
|
285
|
Serial intravascular ultrasound analysis of the impact of myocardial bridge on neointimal proliferation after coronary stenting in patients with acute myocardial infarction.
|
J Interv Cardiol
|
2010
|
0.75
|
|
286
|
Relationship between angiographic dynamic and densitometric assessment of myocardial reperfusion and survival in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: the harmonizing outcomes with revascularization and stents in AMI (HORIZONS-AMI) trial.
|
Am Heart J
|
2011
|
0.75
|
|
287
|
Safety and performance of a novel embolic deflection device in patients undergoing transcatheter aortic valve replacement: results from the DEFLECT I study.
|
EuroIntervention
|
2015
|
0.75
|
|
288
|
Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: two-year results from a prospective patient-level pooled analysis of TARGET trials.
|
Catheter Cardiovasc Interv
|
2015
|
0.75
|
|
289
|
Gamma radiation for in-stent restenosis: effect of lesion length on angiographic and clinical outcomes.
|
Catheter Cardiovasc Interv
|
2004
|
0.75
|
|
290
|
Comparison of catheterization laboratory initiated abciximab and eptifibatide during percutaneous coronary intervention in acute coronary syndromes (an ACUITY substudy).
|
Am J Cardiol
|
2010
|
0.75
|
|
291
|
Favorable effect of gamma-radiation for in-stent restenosis: effect of diabetes on angiographic and clinical outcomes.
|
Catheter Cardiovasc Interv
|
2004
|
0.75
|
|
292
|
Almanac 2013: novel non-coronary cardiac interventions.
|
Acta Cardiol
|
2014
|
0.75
|
|
293
|
Will this trial change my practice? TOTAL: a randomised trial of thrombus aspiration in ST-elevation myocardial infarction.
|
EuroIntervention
|
2015
|
0.75
|
|
294
|
Correlations between epicardial flow, microvascular reperfusion, infarct size and clinical outcomes in patients with anterior versus non-anterior myocardial infarction treated with primary or rescue angioplasty: analysis from the EMERALD trial.
|
EuroIntervention
|
2009
|
0.75
|
|
295
|
Evaluation of XIENCE V everolimus-eluting and Taxus Express2 paclitaxel-eluting coronary stents in patients with jailed side branches from the SPIRIT IV trial at 2 years.
|
Am J Cardiol
|
2013
|
0.75
|
|
296
|
Impact of advanced age on the safety and effectiveness of paclitaxel-eluting stent implantation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: The HORIZONS-AMI trial.
|
Catheter Cardiovasc Interv
|
2013
|
0.75
|
|
297
|
Usefulness of the angiographic pattern of in-stent restenosis in predicting the success of gamma vascular brachytherapy.
|
Am J Cardiol
|
2003
|
0.75
|
|
298
|
Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction.
|
Am J Cardiol
|
2004
|
0.75
|